Predicting patient response to immune checkpoint blockade is difficult, necessitating models that combine it with other therapies for optimal evaluation.

“one of the limitations that we have with immune checkpoint blockade is some of which I've already mentioned we can't identify who's gonna respond if who's not going to respond and we have to extend the responder pool but we have to be able to model that because it's very clear that a single agent is going to be a Munich point blockade therapy is not going to help moe the patients so how do we go about optimizing this treatment and having models where you can combine immune checkpoint blockade with other therapies to evaluate what is the optimal response is critical and that's what we're doing”